This application for renewal of the University of Virginia Cancer Center requests support for leadership, administration, planning, shared resources, and developmental activities. Ours is a matrix cancer center that brings together 196 members from 30 Departments in the School of Medicine, School of Nursing and the Colleges of Arts and Sciences, and of Engineering, all of which reside on a single campus. The Cancer Center has seven research Programs: ? Six basic/translational Programs representing key scientific foci important for understanding cancer. 1-Cell Signaling; 2-Endocrinology;3-lmmunology;4-Migration and Metastasis;5-Structural Biology;6-Molecular Genetics. ? One translational/clinical Program, 7-Developmental Therapeutics, which has two sub-Programs: Immune Therapies;and Targeted Therapies, Biomarkers, and Imaging. This Program has as its principal mission the development and implementation of clinical research that draws on the basic science expertise of the Center. There are 8 members who are not aligned. The Cancer Center supports 14 Shared Resources: Advanced Microscopy, DMA Sciences, Flow Cytometry, Lymphocyte Culture, Mass Spectrometry, Protein Sciences, Small Animal Multimodality Imaging, Tissue Culture, Gene Targeting &Transgenic, Research Histology, Molecular Assessment &Preclinical Studies, Tissue Procurement, Biostatistics, and the Clinical Trials Office. During the past grant period the CCSG assisted in the recruitment of 33 new faculty to the University, and increased its membership by 26. Notable is the formation of a new Program, Molecular Genetics, comprised both of new recruits and previous members. NCI funding for the CCSG has increased from $6,648,872 (annual, direct) to $14,413,544, and total peer-reviewed funding from $32,814,939 to $68,130,838. This period has seen enhancement of the already outstanding basic science, increased cancer focus in every Program, and substantially increased clinical research activity. Clinical facilities have been renovated and expanded and ground has been broken on a new research building which will house our Immunotherapy program and our developing Women's Oncology program. A new clinical building is being planned. Major goals for the next grant period are to expand substantially the clinical research activities that draw on our basic science, further elevate the excellence and cancer focus of the basic sciences, and strengthen the foundation for achieving Comprehensive status at the next renewal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-20
Application #
7771676
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-16
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2012-01-31
Support Year
20
Fiscal Year
2010
Total Cost
$2,410,577
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications